Endonovo Therapeutics, Inc. (ENDV) stock
ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $135.08KP/E –Yield –
Endonovo Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Endonovo Therapeutics's free cash flow for the twelve months ending Dec 31, 2019 was -$2.54M. For fiscal 2019 it was -$2.54M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | -$2.54M | – |
| FY2018 | Dec 31, 2018 | -$2.89M | – |
| FY2015 | Dec 31, 2015 | -$1.02M | – |
| FY2014 | Dec 31, 2014 | -$909.30K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2019 | Dec 31, 2019 | -$308.38K | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.02M | – |
| Q4 FY2018 | Dec 31, 2018 | -$716.10K | – |
| Q3 FY2018 | Sep 30, 2018 | -$830.38K | – |
| Q2 FY2018 | Jun 30, 2018 | -$741.61K | – |
| Q1 FY2018 | Mar 31, 2018 | -$599.72K | – |
See a number that looks wrong?